Concepts (217)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Internal Medicine | 8 | 2021 | 347 | 1.000 |
Why?
|
| Internship and Residency | 9 | 2021 | 1004 | 0.970 |
Why?
|
| Ventilator Weaning | 2 | 2013 | 24 | 0.890 |
Why?
|
| Educational Measurement | 3 | 2021 | 225 | 0.840 |
Why?
|
| Muscle, Smooth | 9 | 2011 | 354 | 0.750 |
Why?
|
| Clinical Clerkship | 1 | 2021 | 116 | 0.700 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2021 | 160 | 0.650 |
Why?
|
| Clinical Competence | 5 | 2021 | 751 | 0.590 |
Why?
|
| Gastroenterology | 4 | 2021 | 134 | 0.580 |
Why?
|
| Serum Response Factor | 4 | 2010 | 44 | 0.520 |
Why?
|
| Education, Medical, Graduate | 5 | 2021 | 369 | 0.480 |
Why?
|
| Ultrasonography | 1 | 2016 | 695 | 0.480 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2013 | 18 | 0.460 |
Why?
|
| Azathioprine | 1 | 2013 | 125 | 0.440 |
Why?
|
| Cytomegalovirus Infections | 1 | 2013 | 144 | 0.430 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 140 | 0.430 |
Why?
|
| Students, Medical | 3 | 2021 | 384 | 0.400 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2010 | 75 | 0.400 |
Why?
|
| Asthma | 9 | 2017 | 955 | 0.370 |
Why?
|
| Liver Diseases | 3 | 2021 | 238 | 0.340 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 977 | 0.310 |
Why?
|
| Colitis, Ulcerative | 1 | 2013 | 711 | 0.280 |
Why?
|
| Curriculum | 4 | 2021 | 539 | 0.230 |
Why?
|
| Career Choice | 3 | 2021 | 139 | 0.230 |
Why?
|
| Hospitals, Teaching | 1 | 2001 | 115 | 0.200 |
Why?
|
| Documentation | 1 | 2001 | 98 | 0.200 |
Why?
|
| Licensure, Medical | 1 | 2021 | 19 | 0.200 |
Why?
|
| Humans | 28 | 2021 | 86653 | 0.190 |
Why?
|
| Medical Staff, Hospital | 1 | 2001 | 107 | 0.190 |
Why?
|
| Accreditation | 1 | 2021 | 60 | 0.190 |
Why?
|
| Trachea | 5 | 2011 | 293 | 0.190 |
Why?
|
| Teaching | 1 | 2001 | 147 | 0.190 |
Why?
|
| Geographic Mapping | 1 | 2019 | 12 | 0.170 |
Why?
|
| Peer Group | 1 | 2019 | 72 | 0.170 |
Why?
|
| Cell Nucleus | 3 | 2010 | 580 | 0.170 |
Why?
|
| School Admission Criteria | 1 | 2019 | 23 | 0.170 |
Why?
|
| Leadership | 1 | 2019 | 134 | 0.160 |
Why?
|
| Semaphorins | 1 | 2017 | 17 | 0.150 |
Why?
|
| United States | 6 | 2021 | 6674 | 0.150 |
Why?
|
| Reference Standards | 1 | 2018 | 159 | 0.150 |
Why?
|
| Serum Amyloid P-Component | 1 | 2016 | 5 | 0.150 |
Why?
|
| HLA-G Antigens | 2 | 2013 | 52 | 0.130 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 190 | 0.130 |
Why?
|
| Male | 13 | 2021 | 40973 | 0.130 |
Why?
|
| Writing | 1 | 2015 | 29 | 0.130 |
Why?
|
| Lung | 3 | 2017 | 1170 | 0.130 |
Why?
|
| Fellowships and Scholarships | 1 | 2015 | 108 | 0.120 |
Why?
|
| Patient Handoff | 1 | 2015 | 93 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 425 | 0.120 |
Why?
|
| Actins | 4 | 2011 | 451 | 0.110 |
Why?
|
| Pulmonary Eosinophilia | 1 | 2012 | 4 | 0.110 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2012 | 11 | 0.110 |
Why?
|
| Epithelial Cells | 1 | 2017 | 669 | 0.110 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2012 | 17 | 0.110 |
Why?
|
| Positive-Pressure Respiration | 1 | 2012 | 41 | 0.110 |
Why?
|
| Cough | 1 | 2012 | 54 | 0.110 |
Why?
|
| Dyspnea | 1 | 2012 | 73 | 0.110 |
Why?
|
| Eosinophilia | 1 | 2012 | 84 | 0.110 |
Why?
|
| Muscle Proteins | 3 | 2004 | 132 | 0.100 |
Why?
|
| Time Factors | 3 | 2015 | 5210 | 0.100 |
Why?
|
| Gene Rearrangement | 1 | 2012 | 170 | 0.100 |
Why?
|
| Microfilament Proteins | 3 | 2004 | 208 | 0.100 |
Why?
|
| alpha Karyopherins | 1 | 2010 | 10 | 0.100 |
Why?
|
| Female | 11 | 2021 | 44537 | 0.100 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 150 | 0.100 |
Why?
|
| Dimerization | 1 | 2010 | 143 | 0.100 |
Why?
|
| Immunoprecipitation | 1 | 2010 | 134 | 0.100 |
Why?
|
| Bronchoalveolar Lavage Fluid | 3 | 2017 | 121 | 0.090 |
Why?
|
| Pneumonia | 1 | 2011 | 179 | 0.090 |
Why?
|
| Guideline Adherence | 1 | 2011 | 223 | 0.090 |
Why?
|
| Green Fluorescent Proteins | 1 | 2010 | 305 | 0.090 |
Why?
|
| Dogs | 6 | 2011 | 685 | 0.090 |
Why?
|
| Muscle Contraction | 3 | 2011 | 284 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 322 | 0.090 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 425 | 0.090 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 2 | 2011 | 44 | 0.090 |
Why?
|
| Leukocytes | 1 | 2010 | 202 | 0.080 |
Why?
|
| Contractile Proteins | 2 | 2011 | 54 | 0.080 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2010 | 203 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2010 | 557 | 0.080 |
Why?
|
| HLA Antigens | 1 | 2010 | 232 | 0.080 |
Why?
|
| Protein Binding | 2 | 2010 | 1457 | 0.080 |
Why?
|
| Heart Arrest | 1 | 2011 | 265 | 0.080 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2011 | 135 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2013 | 534 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2016 | 4213 | 0.080 |
Why?
|
| Myosin Heavy Chains | 3 | 2004 | 88 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 4 | 2006 | 937 | 0.080 |
Why?
|
| Smad7 Protein | 1 | 2006 | 7 | 0.070 |
Why?
|
| Cell Line | 1 | 2010 | 2469 | 0.070 |
Why?
|
| Bronchi | 2 | 2004 | 229 | 0.070 |
Why?
|
| Aged | 4 | 2017 | 18415 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 1036 | 0.060 |
Why?
|
| Algorithms | 1 | 2012 | 1830 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 1 | 2006 | 301 | 0.060 |
Why?
|
| Respiratory System | 1 | 2004 | 116 | 0.060 |
Why?
|
| Models, Biological | 1 | 2010 | 1749 | 0.060 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2004 | 234 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2004 | 262 | 0.060 |
Why?
|
| Protein Kinases | 1 | 2004 | 209 | 0.060 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2003 | 77 | 0.060 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2003 | 83 | 0.050 |
Why?
|
| Adult | 6 | 2021 | 25649 | 0.050 |
Why?
|
| Receptors, Muscarinic | 1 | 2002 | 49 | 0.050 |
Why?
|
| Workload | 1 | 2001 | 128 | 0.050 |
Why?
|
| Data Collection | 1 | 2001 | 372 | 0.050 |
Why?
|
| Animals | 10 | 2016 | 26589 | 0.040 |
Why?
|
| Mutation | 1 | 2010 | 3968 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 2006 | 1208 | 0.040 |
Why?
|
| Education, Medical | 1 | 2001 | 233 | 0.040 |
Why?
|
| Gene Expression | 1 | 2003 | 1284 | 0.040 |
Why?
|
| Cells, Cultured | 4 | 2006 | 2819 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2019 | 256 | 0.040 |
Why?
|
| Hypertrophy | 2 | 2011 | 62 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2004 | 1458 | 0.040 |
Why?
|
| China | 1 | 2018 | 228 | 0.040 |
Why?
|
| Genome, Human | 1 | 2002 | 756 | 0.040 |
Why?
|
| Mucus | 1 | 2016 | 19 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2001 | 636 | 0.040 |
Why?
|
| Ovalbumin | 1 | 2016 | 109 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 1054 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2000 | 696 | 0.030 |
Why?
|
| Middle Aged | 4 | 2017 | 25028 | 0.030 |
Why?
|
| Clinical Audit | 1 | 2015 | 9 | 0.030 |
Why?
|
| Insurance Benefits | 1 | 2015 | 8 | 0.030 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2015 | 23 | 0.030 |
Why?
|
| Allergens | 1 | 2016 | 179 | 0.030 |
Why?
|
| Transcription, Genetic | 3 | 2006 | 1135 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2015 | 194 | 0.030 |
Why?
|
| Feedback | 1 | 2015 | 133 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2015 | 154 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2011 | 1106 | 0.030 |
Why?
|
| Young Adult | 2 | 2017 | 5977 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 2501 | 0.030 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2012 | 2 | 0.030 |
Why?
|
| Decision Making | 1 | 2019 | 642 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2016 | 971 | 0.030 |
Why?
|
| Maternal Exposure | 1 | 2013 | 57 | 0.030 |
Why?
|
| Imatinib Mesylate | 1 | 2012 | 126 | 0.030 |
Why?
|
| Respiratory Mucosa | 1 | 2013 | 88 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 1540 | 0.030 |
Why?
|
| Cytokines | 1 | 2016 | 778 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2012 | 128 | 0.030 |
Why?
|
| Benzamides | 1 | 2012 | 229 | 0.030 |
Why?
|
| Steroids | 1 | 2012 | 177 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2006 | 1014 | 0.030 |
Why?
|
| American Heart Association | 1 | 2011 | 92 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1801 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2011 | 37 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 307 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 364 | 0.020 |
Why?
|
| Piperazines | 1 | 2012 | 272 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2011 | 63 | 0.020 |
Why?
|
| Enzyme Inhibitors | 2 | 2004 | 639 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2012 | 370 | 0.020 |
Why?
|
| Solubility | 1 | 2010 | 177 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2011 | 692 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2011 | 478 | 0.020 |
Why?
|
| Inpatients | 1 | 2011 | 297 | 0.020 |
Why?
|
| Genotype | 1 | 2013 | 1851 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 1187 | 0.020 |
Why?
|
| Phenotype | 2 | 2004 | 2380 | 0.020 |
Why?
|
| Age Factors | 1 | 2011 | 1851 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2011 | 3243 | 0.020 |
Why?
|
| Trinucleotide Repeats | 1 | 2006 | 31 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2006 | 268 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2011 | 1579 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2006 | 1921 | 0.020 |
Why?
|
| Respiratory Tract Diseases | 1 | 2004 | 45 | 0.020 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2004 | 48 | 0.020 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2004 | 36 | 0.020 |
Why?
|
| Transfection | 1 | 2006 | 896 | 0.020 |
Why?
|
| Binding Sites | 1 | 2006 | 1098 | 0.010 |
Why?
|
| Bronchoconstrictor Agents | 1 | 2003 | 12 | 0.010 |
Why?
|
| Thiazolidines | 1 | 2003 | 17 | 0.010 |
Why?
|
| Muscle Cells | 1 | 2003 | 18 | 0.010 |
Why?
|
| Methacholine Chloride | 1 | 2003 | 64 | 0.010 |
Why?
|
| Amides | 1 | 2003 | 60 | 0.010 |
Why?
|
| Elasticity | 1 | 2003 | 94 | 0.010 |
Why?
|
| Histamine | 1 | 2003 | 126 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2004 | 182 | 0.010 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2003 | 76 | 0.010 |
Why?
|
| Receptor, Muscarinic M3 | 1 | 2002 | 12 | 0.010 |
Why?
|
| Bacterial Toxins | 1 | 2003 | 111 | 0.010 |
Why?
|
| Stem Cells | 1 | 2004 | 351 | 0.010 |
Why?
|
| Thiazoles | 1 | 2003 | 131 | 0.010 |
Why?
|
| rho-Associated Kinases | 1 | 2003 | 159 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 393 | 0.010 |
Why?
|
| Risk Factors | 1 | 2011 | 5417 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 2360 | 0.010 |
Why?
|
| Respiration | 1 | 2003 | 262 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2002 | 351 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 6509 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2000 | 20 | 0.010 |
Why?
|
| Transcription Factor AP-2 | 1 | 2000 | 14 | 0.010 |
Why?
|
| Pyridines | 1 | 2003 | 310 | 0.010 |
Why?
|
| Cell Compartmentation | 1 | 2000 | 69 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2002 | 201 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2003 | 379 | 0.010 |
Why?
|
| Serine | 1 | 2000 | 99 | 0.010 |
Why?
|
| Mutagenesis | 1 | 2000 | 199 | 0.010 |
Why?
|
| Exons | 1 | 2002 | 450 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2012 | 7993 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2000 | 281 | 0.010 |
Why?
|
| Biological Transport | 1 | 2000 | 396 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2000 | 270 | 0.010 |
Why?
|
| Rabbits | 1 | 2000 | 636 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2000 | 506 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 1961 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2000 | 736 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2002 | 853 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2004 | 1981 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2011 | 8491 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 2330 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 3030 | 0.010 |
Why?
|
| Calcium | 1 | 2000 | 1156 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2000 | 1565 | 0.010 |
Why?
|